A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)

Epix Pharmaceuticals, Inc.17 sites in 1 country310 target enrollmentAugust 2005

ConditionsAnxiety Disorders

DrugsPRX-00023

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Anxiety Disorders
Sponsor: Epix Pharmaceuticals, Inc.
Enrollment: 310
Locations: 17
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in adults with GAD.

Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who fulfill the inclusion/exclusion criteria, will be enrolled in this study.

Detailed Description

This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in adults with GAD. Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who fulfill the inclusion/exclusion criteria, will be enrolled in this study. This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in adults with GAD. Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who fulfill the inclusion/exclusion criteria, will be enrolled in this study.

Registry

clinicaltrials.gov

Start Date

August 2005

End Date

June 2006

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Epix Pharmaceuticals, Inc.

Eligibility Criteria

Inclusion Criteria

•Be male or female, 18-65 years of age
•Meet DSM-IV diagnostic criteria for Generalized Anxiety Disorder (GAD)
•Have a total score of ≥ 20 on the HAM-A and a score of ≥ 2 on Items 1 and 2 (anxious mood and tension) of the HAM-A
•Have no more than a 20% decrease in total HAM-A score during the period from the screening visit to the randomization visit
•Have a negative serum (β-HCG) pregnancy test at screening and a negative urine pregnancy test at baseline (for all women)
•Female subjects must meet one of the following criteria: (a) Be surgically sterile (i.e., have had bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least six months prior to first dose of PRX-00023; appropriate documentation will be required) OR (b) Agree that, if sexually active, they and all male partners will use two (2) acceptable barrier forms of contraception (e.g., condoms and diaphragm) from screening until one month after the final dose of study drug
•Male subjects must agree that they and any female partners will use two(2) acceptable forms of contraception (e.g., condoms and hormonal contraceptives) from screening until one month following the final dose of study drug
•Be in generally good physical health as determined by the Investigator on the basis of medical history, physical examination, and screening laboratory results
•Have the ability to communicate with the investigative site staff in a manner sufficient to carry out all protocol procedures as described
•Be able to understand procedures and provide written informed consent prior to admission

Exclusion Criteria

•A history of an inability to tolerate, or a failure to respond to, two or more anxiolytic or anti-depressant drugs given in adequate doses and duration for the treatment of symptoms present in the current illness
•Prior intolerance to buspirone, gepirone, tandospirone or other 5HT1A agonist
•A current or past history of mania, bipolar disorder, schizophrenia, or other psychotic disorder
•A current history (or within the six months prior to screening) of panic disorder, post traumatic stress disorder, major depression, obsessive-compulsive disorder, social phobia, acute stress disorder, adjustment disorder with anxious mood, performance anxiety, somatization disorder, or other principle psychiatric diagnosis (DSM-IV) which could interfere with the efficacy assessments
•A history of a major life event (e.g. divorce, death of family member) which in the opinion of the Investigator is likely to alter the efficacy ratings during the course of the study
•Clinically significant abnormalities on laboratory tests or ECG (includes QTc value \>450 msec in males or \> 470 msec in females)
•The presence of a serious or clinically unstable neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematologic or other medical illness or psychiatric condition that would, in the opinion of the Investigator, compromise participation in the study, confound study results, or likely lead to the need for early termination of study participation or hospitalization during the course of the study
•A history of allergic reactions to two or more medications of different chemical classes
•Use of any non-prescription drug with psychotropic effects within seven (7) days prior to initiation of the placebo lead in
•Chronic use of analgesics with opiates (e.g., codeine, hydrocodone, oxycodone) for \>6 months or use of opiates within two weeks prior to screening